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Abstract Drug development is being continuously scrutinised
for its lack of productivity. Novel drug development is associated
with high costs, high failure rates and lengthy development pro-
cess. These downfalls combined with a huge demand in blood
cancer for new therapeutic treatments have led many to consider
the method of drug repurposing. Finding new therapeutic indi-
cations for already established drug substances is known as
redirecting, repositioning, reprofiling, or repurposing of drugs.
Off-patent and on-patent drugs can be screened for additional
targets and new indications thus bringing them to clinical trials at
a faster pace. This approach offers smaller research groups, such
as those that are academic based, into the drug development
industry. Drug repurposing can make use of previously pub-
lished data concerning dosage, toxicology and mechanism of
activity.
Keywords Blood cancer . Drug repurposing . Review
Introduction
Cancer is a major cause of death in the world today, and its
level of incidence is set to increase globally putting pressure
on health services and pharmaceutical companies to develop
novel therapies at a competitive pace.
The current model of drug discovering is being continu-
ously scrutinised due to the high failure rate that has been
recently associated with it. Finding new therapeutic indica-
tions for already established drug substances is known as
redirecting, repositioning, reprofiling, or repurposing of drugs
[1]. For the purpose of this review, the strategy will be known
as repurposing of drugs. This method of developing novel
drug treatments is becoming increasingly more attractive as
an alternative to the current methods due to the huge reduction
in time needed to achieve accreditation and introduce the drug
into the market [2].
In the past decades, the number of novel drugs being intro-
duced into the market has had not significantly increased,
even with recent advances in technology both informational
and biological. The total research and development (R&D)
spending for drug discovery worldwide has increased at least
15-fold from 1975; however, the number of new molecular
entities (NMEs) approved by the Food and Drug Administra-
tion (FDA) in the USA did not show a similar dramatic in-
crease: 26 new drugs approved in 1976 and 41 novel new
drugs approved in 2014 [3–5].
In total, the time for drug discovery and development is
around an average of 13 years of research and financial in-
vestment resulting in the drug being brought from the labora-
tory to a patient’s bedside (Fig. 1). The process of drug devel-
opment entails multiple steps and phases of trials that attempt
to seek FDA approval. The steps prior to clinical trials involve
testing the efficacy, toxicity, and pharmacokinetic and phar-
macodynamic profiles of the drug which usually take place by
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cell- and animal-based studies. Following the success of these
steps, the drug will be then tested for efficacy and safety in
human subjects, which usually occurs in three phases [6]:
& Phase 1 studies are focused on the safety of the drug.
& The drug will proceed to phase 2, only if it is not found to
have unacceptable levels of toxicity, to test the effective-
ness of the drug and its ability to successfully interact with
its predetermined target. Usually in phase 2, patients with
a specific disease are treated and often when refractory or
resistant to previous therapies.
& Phase 3, the final stage, continues to evaluate safety and
effectiveness but also tests the therapies against standard
of care treatments or different doses often in a randomised
trial basis. This phase usually requires significant numbers
of patient subjects to allow for the generation of significant
and reliable data to show significant benefit.
FDA approval is usually given following successful com-
pletion of phases 1, 2, and 3, which can take several years
(Fig. 1). It is very common to see drugs fail to effectively
target the disease in which they have been developed for or
they are proved to be unsafe in humans and therefore do not
receive FDA accreditation.
The pharmaceutical industry faces significant challenges,
both politically and financially. In a study carried out by Tufts
Center for the Study of Drug Development in 2014, the esti-
mated cost to develop a new drug that gains marketing ap-
proval costs $2558 million, a significant increase compared to
the previous study, in 2003, which estimated the cost to be
$802 million [7]. This rise puts pressure on companies to
insure drugs being developed do receive approval and results
in the pricing of drugs rising significantly when in market,
making them less affordable for health care centres and pa-
tients. Governments around the world are trying to contain
costs, and, as health care budgets constitute a large part of
governmental spending, these costs are the subject of intense
scrutiny. In the USA, as elsewhere, drug costs are also the
subject of intense political discussion [8].
The demands of blood cancer
All cancers demand new treatments, and in this review, we
focus on one specific type of cancer: blood cancers or haema-
tological malignancies. There are four broad categories of
blood cancers: leukaemia, myeloma, Hodgkin lymphoma
and non-Hodgkin lymphoma. Together, these account for
around 9 % of all cancers and are currently the fourth most
common in both males and females in the world [9].
But these four categories contain over 60 different sub-
types, as first highlighted in 2001, and then in 2008, when
the World Health Organisation (WHO) produced an accepted
classification of haematologic malignancy that defined each
type according to immunophenotype, genetic abnormalities
and clinical features [10, 11]. This was the first time that the
genetics of the disease was combined with morphology, cyto-
chemical and clinical information to define the classification
of the disease. In the USA, it is estimated that a total of 157,
000 people would have been diagnosed with a blood cancer in
2014, and that around 55,000 people would die in the USA of
a haematology malignancy [12].
The high incidence and mortality rates highlight the need
for the development of novel and effective treatments. It is
also necessary that these drugs be introduced into the market
at a much faster rate. Between 2005 and 2014, the FDA ap-
proved 268 new molecular entities (NMEs) [5], although only
~10 % of these NMEs had an indication for haematologic
malignancies [13]. Overall, 23 of the 84 FDA cancer drug
approvals in the past 5 years were associated with blood can-
cers (Table 1). Furthermore, of the cancer drugs which gained
Fig. 1 Comparison of the phases
and timescale required for de
novo drug discovery or
repurposing drugs
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FDA approval in 2012, 11 were priced at more than $100,000
per patient per year, prices which are simply unaffordable to
the majority of patients and almost all medical services [14].
One of the earliest targeted therapies, imatinib, branded as
Gleevec, saw its market price rise from £18,000 to £21,000 in
the UK per patient per year. Gleevec is hugely successful and
thus a profitable drug for the pharmaceutical company,
Novartis, with an indication for the treatment of chronic my-
eloid leukaemia (CML) and many others. Whilst all the initial
research and development cost had already been covered, the
increased cost was probably based on its success.
Recognising the major issues associated with cancer in
regard to the lack of effective treatments, multiple projects
have been set up in an attempt to develop new processes to
find novel therapies. One such project is the Repurposing
Drugs in Oncology (ReDO) project [14].
The ReDO Project is a collaboration between Global Cures
of the USA and Anticancer Fund in Belgium with the aim of
the project is to find existing drugs which are non-cancer
related and test their potential for becoming novel, repurposed
treatments for cancers [14]. The success rate for new oncology
drugs in phase I trials is 6.7 %, half the rate of non-oncological
drugs [14]; therefore, the cost of oncology drug development
impacts vastly on the health and global economy each year.
So, the approach of drug repurposing should ease the pressure
to contain costs by reducing the early-stage research and de-
velopment costs associated with the current drug development
model. One of the main concerns is the future economic im-
pact the increasing incidence of cancer will have on the price
of new therapeutic treatments. Costs for these treatments are
increasing due to high failure rates and decreasing investment
[15], whilst many approved drugs are not specific enough for
the rare and mutated forms. Tumours become resistant to cur-
rent treatments and displaying high levels of intra-tumour ge-
netic heterogeneity, and so, treatments are probably acting as
selective pressures [15]. For this reason, targeting treatments
with single compounds will not be effective against resistant
tumours. It is clear that new and repurposed drugs should be
considered in combination with other targeting compounds
against a tumour or be prescribed at earlier stages of the dis-
ease. Combinations between targeted therapies and traditional
chemotherapeutic agents are now being widely used [16].
The ReDO project recognises that there are multiple
sources of anticancer drugs apart from existing pharmaceuti-
cal armamentarium. The project intends to repurpose non-
cancer drugs, which are well known, and find a new indication
for these drugs as anticancer treatments [14]. In 2014, ReDO
published an initial report addressing the current problems in
oncology, stating the objectives of the project and the first six
compounds which were considered to be potential candidates
for repurposing. The six compounds were selected based on
the fact that they are well known, generic drugs with well-
detailed toxicology publications. The six compounds are
mebendazole, nitroglycerin, cimetidine, clarithromycin,
itraconazole, and diclofenac. To date, the project has pub-
lished evidence for the anticancer activity of cimetidine,
clarithromycin and mebendazole, with Mebendazole being
evaluated for its effectiveness in leukaemia [17–19].
Advantages of repurposing drugs
The most accepted argument in favour of this method of drug
development is the reduced research and development time
involved in bringing the drug to market and to the patient’s
bedside. It has been estimated the development of novel drugs
can take up to 17 years; whereas, the process of repurposing a
drug may only be 3–12 years (Fig. 1) [1]. Repurposing drugs
offers a high level of safety as there is already a wealth of
accessible data describing the pharmacokinetics, toxicities,
bioavailability, dosing, and protocols of the agents [16]. As
~30 % of trial drugs fail due to safety and repurposed, drugs
hold an advantage of a reduced failure rate as they have al-
ready been tested for safety. Phase I clinical trials usually
allow for dosage limits to be identified and may be avoided
or use predetermined dosage schedules for the trial [16], and
the cost of a relaunch is reduced compared to a launch of a
novel compound.
Potential barriers and limitations to drug repurposing
Some limitations have arisen when repurposing drugs. In var-
ious cases, a drug may show good efficacy for a new indica-
tion but at a much higher dosage than previously approved
resulting in possible adverse effects relating to toxicity [16].
Research companies can be focused on certain disease areas,
and so, potential indications for drugs can go untested [20].
Patent exclusivity can play a major role in limiting the poten-
tial of repurposing a drug. Drug patents are required by the
developing pharmaceutical company so they are the only
company able to manufacture, market, and avail of any profits
made from the drug.
However, in the USA, a patent provides protection for up to
20 years, counting from the filing date. A similar length of 20-
year patent protection is granted by the European Patent Con-
vention (EPC). It is normal that a pharmaceutical company
will apply for patency prior to commencing clinical trials.
When a patent expires, the drug is termed ‘generic’ and so is
available for other companies to manufacture and market. A
good example of this process is paracetamol whose patent
expired in 2007; since then, numerous versions have arisen
and developed under many different brands [21].
The patent on the basic compound patent for Gleevec
(imatinib) expired in the USA in July 2015, and in 2016, in
major European countries, although for other polymorphic
forms of Gleevec, the patent expires in 2019. There are also
Ann Hematol
generic versions waiting to seek approval from the US Food
and Drug Administration (FDA), which will be marketed at a
much lower cost than the current price per patient per year.
Litigation in 2014 resulted in Novartis permitting a subsidiary
of Sun Pharma to market a generic version of Gleevec in the
USA from February 2016 [22].
Current regulations relating to drug development can also
act as a deterrent for repurposing drugs for some research
groups. Strict legislations are involved when repurposing a
patent drug. On-patent drugs can be screened for new indica-
tions without the need of chemistry and manufacturing appli-
cations or seeking the approval of the original owners provid-
ing that the product is used in agreement with the approved
product label. In the case of off-patent or generic drugs, the
new indication must be novel and have clinical benefits. For
both of these indications, the new claim must not have been
previously published or suggested in past literature. A major
deterrent for research is the necessity to develop a new formu-
lation so as to have the ability to achieve market exclusivity
with the proposed new indication. An incentive for groups to
take on this process is the Orphan DrugAct (ODA) which was
set up in 1983 to encourage pharmaceutical companies to
address the need for novel treatments for rare diseases [23,
24]. The European Union defines rare diseases as being those
that affect less than 5 in 10,000 of the general population,
whilst in the USA, an orphan disease affects less than 200,
000 of the whole population. Haematological malignancies
including AML, chronic myeloid leukaemia (CML) and mul-
tiple myeloma (MM) are known as rare and orphan diseases.
The ODA offers pharmaceutical companies incentives to ap-
ply their research into developing treatments for such rare
diseases.
Funding of grants and contracts may be given if the re-
search is put towards an orphan disease. The FDA will also
accept smaller patient numbers for trial when reviewing appli-
cations for orphan drug. Drug applications are usually associ-
ated with fees; however, in these causes, such fees are not
claimed. If approval is awarded, amarket exclusivity of 7 years
in the USA and 10 years in the European Union is given under
the ODA. Since the passing of the act in 1983 up until 2010,
the FDA have approved 353 orphan drugs and granted orphan
designations to 2116 compounds via the Office of Orphan
Product Development (OOPD) of the FDA. This focus on
orphan drugs and diseases has continued as of the 27 drugs
approved by the FDA in 2013, 9 of these were for the treat-
ment of rare diseases [20].
Types of repurposing
In general, there are two simple concepts behind recognising
the potential of a drug to be repurposed for a new indication.
The first of these concepts is the identification of a drug to
interact with multiple targets relatable to multiple diseases.
These additional targets, i.e. off-targets, can arise serendipi-
tously through screening or observed side effects. In some
cases, these secondary targets cause the drug to be labelled
as ‘dirty’ for the specified indication due to the undesired side
effects produced. However, a certain target can prove benefi-
cial for a new indication. Where a drug is found to have ben-
eficial off targets, it can be known as being ‘desirably promis-
cuous’. The second concept is identifying multiple diseases,
where one target is relevant to the progression of them all. The
discovery of these new indications often occurs from a known
target-based screen of a library of established and/or shelved
compounds such as the Johns Hopkins library, which includes
3500 drugs.
To date, the most successful opportunity for drug
repurposing arises serendipitously, most frequently due to ob-
served side effects. Thalidomide is a prime example of such
serendipitously observations leading to its repurposing for
leprosy and multiple myeloma and explored further later in
the review [25].
Drug repurposing can be applied at many phases of drug
discovery and development but has a greater potential when
the drug has already been tested for safety and efficacy.
Understanding the biology behind a disease is of particular
importance when seeking to repurpose a drug. Knowing the
mechanisms behind which a disease progresses is essential for
identifying targets for its prevention. Imatinib was identified
for new indications through studying its mechanisms
(discussed later).
Methods of drug repurposing
Blinded search or screening methods
These types of methods are based on blinded searches without
considering any known pharmacology or biological data and
often result from serendipitous observations [26]. Blinded
searches and screens have the advantage of flexibility associ-
ated with the application to a diverse number of target diseases
[27]. Between 1999 and 2009, around 34% of FDA-approved
small molecules and biologics were identified via this method.
Drugs repurposed beyond their labelled indications approved
by the FDA using this method include sildenafil citrate for
erectile dysfunction, rituximab in breast cancer, and etoposide
for bladder cancer [28].
Target-based methods
Target-based methods of drug repurposing involve high-
throughput screening both, in vivo and in vitro, of drugs.
The screening aims to identify a drug with a particular bio-
marker or protein of interest from a complex library of
Ann Hematol
compounds [29]. The likelihood of a successful discovery of a
potential drug is much higher than with the blinded screening
method as most of the targets will link directly to the mecha-
nisms of disease. Target-based repurposing allows for large
libraries of drugs or compounds to be screened efficiently
within a few days. This method is particularly popular with
research groups when attempting to develop new treatments
[30].
Knowledge-based methods
A bio- or chemo-informatics analysis is applied in a
knowledge-based method of drug repurposing. The utilisation
of information already available from clinical trial informa-
tion, drug-target networks, identified chemical structures of
drugs and their target, and pathways involved in the drug
activity is used in this method [31]. Researchers using the
knowledge-based method avail of the published information
to predict similarities in drugs and recognise potential new
targets. This enables the identification of new targets for the
drug, which would not be possible in the previous two
methods. Drug repositioning has improved using this method
as it is associated with a reduced failure rate especially if the
drug has already been successful in gaining FDA approval
[32].
Signature-based methods
Gene signatures derived from disease ‘omics’ data with or
without treatments are applied in signature-based methods to
find unknown off-targets or unknown disease mechanisms
[33, 34]. The volumes of genomics data available are increas-
ing exponentially with advances in microarrays and next gen-
eration sequencing techniques. These advances are significant
for the repurposing of drugs as genomic databases are contin-
uingly built upon. Unknown mechanisms of drugs can be
revealed via this method. Computational approaches are par-
ticularly important in signature-based methods [26]. Sirolimus
was repurposed with this method for patients with acute lym-
phoblastic leukaemia with dexamethasone resistance by
linking diseases treated by drugs by using gene signatures
[35].
Pathway- or network-based methods
Similarly to signature-based methods, pathway- or network-
based methods of drug repurposing utilise disease omics data.
In addition, this method uses available signalling or metabolic
pathways and protein interaction networks to recreate disease-
specific pathways that provide the key targets for repositioned
drugs [36]. The main advantage of this method is the use of
large amounts of diverse information to narrow general
signalling networks to a specific network with few proteins/
targets [32].
Targeted mechanism-based methods
Targeted mechanism-based methods identify unknown mech-
anisms of drug action by combining information based on
protein interaction networks, signalling pathways, and treat-
ment omics data. This method is proving particularly impor-
tant in studies where patients can develop resistance to a drug
after initial success indicating that successful drug treatment
must also include studies of the mechanism of drug action
allowing better drug targets to be identified [30]. The signifi-
cant advantage of this method is the potential to identify the
mechanisms related to the treatment of drugs in their specific
diseases [26]. Overall, the methods of drug repurposing share
a common sequential process consisting of analysis, hypoth-
esis generation and validation.
Examples of repurposed drugs in blood cancers
Thalidomide
Thalidomide was developed in the 1950s as a sedative and
was used to alleviate morning sickness in pregnant women.
However, it was noted that the drug could cause serious birth
defects which led to the withdrawal of thalidomide from the
market. During this time, it was estimated that at least 10,000
infants were born with malformations of the limbs and other
body extremities in over 46 countries at this time [37]. In the
later decades, researchers, such as pharmaceutical company
Celgene, continued to test thalidomide for therapeutic effects.
During this period of research by D’Amato, working in the lab
of Judah Folkman, demonstrated that thalidomide significant-
ly reduced neo-vascularisation [38]. Eventually, the drug was
tested in patients with refractory multiple myeloma where it
induced durable responses [39] through its ability to inhibit
tumour necrosis factor alpha. The FDA approved thalidomide
in 2006 as a treatment for multiple myeloma in combination
with dexamethasone.
Imatinib
It is common for cancer therapeutic drugs to be repurposed
within the wider disease subtype they have been initially ap-
proved for. For example, imatinib mesylate, Gleevec, was
originally approved for the treatment of chronic myelogenous
leukaemia. But as imatinib is an inhibitor of the ABL kinase, it
also showed to cross-reactivity with, and an ability to inhibit,
KIT kinase. Mutations causing the activation of the KIT tyro-
sine kinase were identified as a cause in gastrointestinal stro-
mal tumours (GISTs) [40], suggesting that imatinib be tested
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for efficacy against GISTs. Preclinical studies were conducted
to tests the hypothesis of the potential indication and revealed
imatinib did induce cell death in GISTcells which appeared to
be related to inhibition of KIT kinase. These studies resulted
in imatinib being approved of the treatment of GISTs [40].
Imatinib is now used for different blood cancer indications
such as acute lymphoblastic leukaemia, chronic eosinophilic
leukaemia and myelodysplastic/myeloproliferative neoplasms
and also received approval for the treatment for systemic
mastocytosis and dermatofibrosarcoma due to reaction with
the platelet-derived growth factor receptor kinase [36].
Dasatinib
Similarly to Imatinib, dasatinib was initially approved for the
treatment of chronic myeloid leukaemia (CML) and
repurposed for the treatment of patients with Philadelphia
chromosome-positive acute lymphoblastic leukaemia (ALL)
with resistance or intolerance to prior therapies. Dasatinib,
manufactured under the name Sprycel as an oral tyrosine ki-
nase inhibitor, is also in clinical trials for the treatment for
glioblastoma [41] and has also been repurposed by network-
based methods for breast cancer brain metastases by
reconstructing the disease-specific networks to identify key
targets [42].
Improving the success of repurposing drugs
The success of drug repurposing is centred on its ability to
improve efficacy.With the process availing of previously pub-
lished toxicology and clinical information, there is a reduced
risk of failure with the increased safety of the drug.
Along the complete process of novel drug development,
there are multiple stages at which a drug can be predicted
and validated to have an additional indication. As expected,
the further along the progression of the discovery and devel-
opmental process, the more confidence can be associated with
drug repurposing prediction. There are multiple different
methods that can be applied along the timeline of drug devel-
opment: the first of which is a large-scale approach involving
gene profiling and molecular modelling. This first approach
provides a low level of predictability due to the amount the
candidates involved. Large pharmaceutical companies can ap-
ply this approach to every drug they develop. One limitation
to large-scale approach is the need for complex technology
usually inaccessible by smaller research and academic groups.
Adding to the complexity of this approach is the decision on
what to focus on in regard to repurposing the drug. A compa-
ny can test individual drugs for second targets within the same
indication or find a second indication for the drug. They can
also seek to establish if the drug is effective in rare or orphan
diseases (which can present with benefits to the company), an
important decision is whether or not the company will consid-
er all compounds available or only those that they have devel-
oped themselves. A second-step drug development relates to
clinical trials and the observation of side effects experienced
by treated patients. On observation of side effects of interest,
separate clinical trials must be conducted to establish if the
effect is reproducible.
An additional method, although much more time consum-
ing than any previously discussed, is reviewing data of a pa-
tient who is prescribed with a particular drug of interest. This
is a relatively simple approach to initial repurposing prediction
through finding drug and disease relationships. Considering
the scenario of a patient treated with a particular drug for one
indication, it could be observed to have a therapeutic effect for
any additional diseases the patient may possess and so present
with a potential for repurposing investigations.
An important topic to cover when discussing drug
repurposing is the need for animal models. The use of mouse
models is believed necessary to the development of novel
drugs. Mouse models are often used to test the efficacy of a
compound. When the pharmacokinetics of a drug differs
greatly between mouse and human trials, it can be impractical
to mimic dosing schedules in humans. From this, it may be
unjustified to approve the proceeding of human clinical trials
for a new indication [13]. Some suggest animal models can be
skipped if dosing remains constant in repurposing; however,
the case is often not so simple and new indications can require
different dosages which will require mouse models for effica-
cy testing.
Future directions and conclusions
The understanding of disease pathology is continuingly grow-
ing through new technologies allowing us to specify the bio-
logical mechanisms behind the cause of the disease and its
continued invasion. There are two popular approaches to im-
proving the productivity of drug development: drug
repurposing and personalised medicine. Drug efficacy plays
a major role in drug failure. At least 30 % of drugs are failing
due to poor efficacy [8]. Personalised medicine aims to treat
patients based on grouping them with diseases into subtype-
specific treatments in an attempt to improve drug efficacy. A
major impact on efficacy is the complexity and heterogeneity
of human diseases. Blood cancers, in common with other
cancers, are groupings of many diseases each with subtypes
some affected by gene expression profiles. Personalised med-
icine plans to diagnose patients and prescribes treatments
which are specific and tailored to the molecular biology basis
of the disease [43]. With increasing knowledge of the muta-
tions and biology of diseases, personalised medicine is be-
coming increasingly evident and a future direction for patient
treatment. The ability to sequence a person’s DNA means
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there is the potential to characterise a patient’s disease and its
molecular composition and mechanism.
The goal of personalised medicine and the potential of drug
repurposing are a powerful combination which share a com-
mon possibility of developing treatments for rare disease and
those diseases termed ‘orphan’. Often the inadequate numbers
of patients for rare diseases means that clinical trials are im-
possible due to the difficulty in recruiting sufficient numbers
of patients [43]. Drug repurposing can deliver therapies to
these patients, including those with blood cancers, in a more
efficient and timely manner.
It is recognised that there are three key elements necessary
for drug repurposing to have a successful future. The first of
these is the availability of compounds and the information
which is concerning safety and previous clinical studies. Fur-
thermore, it is proposed that a list of compounds along with
the associated information be made to all research and aca-
demic groups. The second element is to be open to investigat-
ing a broad indication space when screening for potential can-
didates. This can be carried out as one project group or mul-
tiple subgroups. Finally, the third key element is maximising
and combining ideas through coupled or multiple collabora-
tions between all sizes of research groups [20].
In order to aid continual repurposing research, it is essential
that research groups have or have access to a physical collec-
tion of drug compounds. These collections of drugs or drug
databases can be subjected to high-throughput screening.
Some already established databases include The Rare Disease
Repurposing Database (RDRD) and The National Clinical
Guidance Centre (NCGC) Pharmaceutical Collection (NPC).
The RDRD is a promising novel resource provided by the
FDA [44]. This database publishes a comprehensive list of
over 200 known products that have the potential to be
repurposed to treat rare diseases. This resource is rich in in-
formation and offers sponsors a new tool for finding special
opportunities to develop niche therapies for rare disease
patients.
The NCGC-NPC is an established, broad, and open access
database of approved and investigational drugs enabling
repurposing and chemical genomics [20]. NPC Informatics
Resource is available for virtual screening by any investigator
with an internet connection. NPC is encouraging the sharing
of drug collection, and in turn, the company requests re-
searchers to share any findings and testing carried out with
aid of the collection whether successful or not. Importantly, all
the data collected from related studies will be made available
publically [45].
In regard to haematologic malignancies alone, the Leu-
kaemia and Lymphoma Society (LLS) has recently devel-
oped The Therapy Acceleration Program (TAP) with aim
of speeding up the development of blood cancer treat-
ments and supportive diagnostics [46]. The program also
supports the drug repurposing projects. TAP comprises
three divisions each with the sole aim of the program.
The first division, the Academic Concierge, capitalises on
the $63 million academic annual investment through
grants. This division encourages further development of
projects that have clinical promise. With disease and re-
search experts in this division, projects are also aided
through guidance in the drug development process and
clinical trial and approval applications. The second divi-
sion is The Biotechnology Accelerator. The main focus of
this division is to identify and support small pharmaceuti-
cal companies that are developing novel blood cancer ther-
apies but lack the expertise or technologic resources to
allow for the full potential of the study and benefit pa-
tients. The final division, The Critical Trials Division, con-
cerns the patients of blood cancers. This division provides
patients with the tools to access relevant clinical studies.
This highlights that for effective repurposing, a partnership
is needed, a partnership that involves the research commu-
nity, the pharmaceutical industry, regulatory authorities,
charities and, perhaps above all, the needs of the patient.
Conclusion
When it is considered that only 3 (7.3 %) of the 41 FDA-
approved novel new drugs in 2014 [5] had indications for
haematologic malignancies, it is obvious that new methods
for drug development are necessary. Drug repurposing offers
this opportunity with a decreased failure rate and lower costs.
Some cases or repurposing leads to a new indication of a drug
compound while others provide the opportunity to second-
generation groups which are more potent and specific with
the same indication. This method also offers the chance for
small research and academic groups to participate in the drug
development process.
It is evident that drugs have the potential to be
repurposed at multiple steps. Drugs that have been with-
drawn, approved, currently in clinical trials or have failed
clinical trials all may have repurposing opportunities. In-
creasing the potential repurposing avenues is based upon
the collaborations of diverse research groups and the shar-
ing of new findings between charitable organisations, aca-
demic groups, and industries. It is expected that the as-
sessment of a drug repurposing potential will become rou-
tine for every drug that has passed through a phase I
clinical trial and already approved drugs. Often, blood
cancer drugs are repurposed for other cancer indications
or additional haematological malignancies; very few are
repurposed as novel treatment of blood cancers from other
disease. However, as a note of caution, any attempt to
identify new therapeutic treatments for hematologic malig-
nancies from repurposed drugs will still require detailed
analysis of the mechanisms behind the drugs activity.
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But repurposing will contribute to improving and increasing
the therapeutic armoury available for blood, and other, cancers.
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